Nectar Lifesciences Ltd. · NSE:NECLIFE
Nectar Lifesciences — Q2 FY2025 Earnings Presentation
31 slides from Nectar Lifesciences's earnings presentation, Nov 14, 2024
Slide 1: Nectar Lifesciences Ltd. exchange filing cover letter
Nectar Lifesciences Ltd. Ref: NLL\CS\2024- 428 November 14, 2024 To 1. National Stock Exchange of India Limited 2. BSE Limited Listing Department, Corporate Relationship Department, Exchange Plaza, Bandra Kurla Complex, P J Towers, Dalal Street, Bandra (E), Mumbai 400 051 Mumbai 400 001 Symbol: NECL
Slide 2: Nectar Lifesciences Ltd. November 2024
Nectar Lifesciences Ltd. November 2024
Slide 3: Disclaimer
DISCLAIMER In this presentation, we have disclosed forward- looking information.. This presentation is based on certain forward looking statements that we periodically make to anticipate results based on the management’s plans and assumptions. We have tried wherever possible to identify such stateme
Slide 4: About the Company - Nectar Lifesciences Ltd
ABOUT THE COMPANY- NECTAR LIFESCIENCES LTD
Slide 5: Nectar Lifesciences Ltd business structure
Nectar Lifesciences Ltd Listed on the Indian Stock Exchanges Allied Business API Formulations Empty Hard Gelatin Capsules Nectar PT Unipessoal LDA Portugal Subsidiary Company Holding Company for IPR
Slide 6: Geography & Locations
Geography & Locations Baddi Barotiwala Landmark Location Activity Dera Bassi Corporate Chandigarh Corporate Functions HQ Global • Marketing & BD Chandigarh • Finance & Accounting • Supply chain • Secretarial & Legal API Manufacturing Derabassi, Punjab Oral & Sterile APIs Unit I API Manufacturing Der
Slide 7: Landmark Timeline
LANDMARK TIMELINE 1995 2020-21 Nectar Lifesciences was Founded Ranked 119 among most emerging countries by Fortune India Next 500. 2019 2007 Bagged Outstanding export performance by API Manufacturing Unit was inaugurated Pharmexcil National Energy conservation award (NECA) 2008 2018 Formulation manu
Slide 8: Our Strengths
OUR STRENGTHS Well equipped to scale and capture large market share Leading 44 DMF’s filed, manufacturers 9 CEP’s & 4 of MAP’s ●120 + Acre API campus. Cephalosporin approved, 15 ●One of the leading API Products ANDA filings manufacturers in the World. ●State of the art facilities . Competitive Estab
Slide 9: Transformation from small domestic API player to global player
Transformation: Evolved from a small domestic API player to a major global player in the Cephalosporins industry. Global Reach: Strong presence in API and formulation business in nearly 45 countries. Manufacturing Facilities: Operates state-of-the-art manufacturing plants in Punjab and Himachal Prad
Slide 10: R&D Infrastructure
R&D INFRASTRUCTURE PROCESSES • LCMS/MS • Sterile Crystallization & • Ion Chromatography Lyophilization Preparative HPLC • Asymmetric Synthesis • Freeze Dryers • Chemical Resolution • HPLC • Enzymatic Catalysis • Gas chromatography • Amino acids • UV photometer • Infrared spectroscopy ANALYTICAL R&D
Slide 11: Global Cephalosporins Drug Market 2020-30
Global Cephalosporins Drug Market 2020-30 Global Cephalosporin Market Share Inj Oral 25.0 23.0 23.6 22.3 21.1 21.7 19.9 20.5 20.0 19.3 17.9 18.5 17.3 15.0 USD Billion 10.0 5.0 0.0 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 Year The global cephalosporin drugs market size was valued at USD
Slide 12: Cephalosporin Global Landscape
Cephalosporin Global Landscape World Pharmaceutical Market: $1.2tn Antibiotics Market: $100bn (Gen I-V) Ceph Market: $19bn (Gen I-V) $16bn Addressable Market for the company Note: All figures in US$
Slide 13: Nectar Lifesciences API Leadership
Nectar Lifesciences API Leadership Oral Cephalosporin Sterile Cephalosporins Cefuroxime Axetil Cefotaxime Ceftriaxone Cefixime • NLL has leading global Crystalline Sodium Sodium Cefuroxime capacities in Cefixime, Axetil Cefuroxime Amorphous Cefuroxime Axetil Sodium Amorphous, Cefuroxime Cefpodoxime
Slide 14: Nectar Lifescience's Global Reach
Nectar Lifescience’s Global Reach Europe Belarus Russia Bulgaria Slovakia Hungary Spain Kazakhstan Turkey Romania Ukraine New Markets Japan, Korea, Latin America China Brazil Ecuador Cambodia Mexico Colombia Venezuela Asia Pacific Afghanistan Nepal Bangladesh Pakistan Africa & Middle-East Cambodia P
Slide 15: API Manufacturing Unit 1
API Manufacturing Unit 1 14
Slide 16: API Manufacturing Unit 2
API Manufacturing Unit 2
Slide 17: API's and Sterile Facility
API’s and STERILE FACILITY ❑This facility has: ▪ Reactors of varied construction features. ▪ Together with matching capacities of centrifuges, driers and various other production equipment. ❑Spray drying facility for Cefuroxime Axetil Amorphous.
Slide 18: API Unit Accreditations
API Unit Accreditations anoeaTUReS JAPAN PORTUGAL South Korea Eel Give GMP 2 .da dp infarmed Qe Autoridade Nac! ‘onal do Medicamento Mistry of Food and Drug Safety e Produtos de Satide I.P. BRAZIL MEXICO AL HUNGARY = Cofepris 8 : Pfepris > Py OGYE Comisién Federal para la Proteccién Orszdgos Gyégysz
Slide 19: Nectar API Global Business Presence
Nectar API Global Business Presence
Slide 20: Formulation Unit Accreditations
Formulation Unit Accreditations
Slide 21: Formulation Facility
FORMULATION FACILITY
Slide 22: Nectar FDF Global Business Presence
Nectar FDF Global Business Presence
Slide 23: Management Expertise and Bandwidth
Management Expertise and Bandwidth Strong relationships with global innovators, Strong management leading customers and team having immense key suppliers as a part expertise in of vertically integrated Pharmaceutical Industry supply chain management Deep seeded Proven ability in management running b
Slide 24: NLL - Self-Sufficient Organization
NLL - Self-Sufficient Organization • 2*6 MW capacity plant in API Unit-II Derabassi, Pb. • We at NLL strongly believe in replacement of organic solvents • Solvent reduction is the sweet spot for greening any with safer available aqueous solvents & similar other pharma process. available options to p
Slide 25: Cephalosporins - Long Chain and Pipeline
Cephalosporins- Long Chain and Pipeline Generation 1- Cefalexin,Cefadroxil,Cefazolin,Cefapirin,Cefacetrile,Cefaloglycin,Cefalonium,Cefaloridine,Cefalotin, Cefatrizine,Cefazaflur,Cefazedone,Cefradine,Cefroxadine,Ceftezole. Generation 2- Cefuroxime,Cefprozil,Cefaclor,Cefonicid,Cefuzonam,Cefamandole,Ce
Slide 26: Competitive Advantage of Nectar
Competitive Advantage of Nectar 1 Expertise and Experience Nectar has over two decades of experience in the manufacturing and distribution of high- quality, cost-effective Cephalosporin and other antibiotics. Marketing and Distribution Our extensive network of distribution channels, supply chain cap
Slide 27: Financials
FINANCIALS
Slide 28: Income Statement & Financial Summary
Income Statement & Financial Summary INR Lacs S. No. Particulars Quarter Ended Half Year Year Ended 30-Sep-24 30-Jun-24 30-Sep-23 30-Sep-24 30-Sep-23 31-Mar-24 Unaudited Unaudited Unaudited Unaudited Unaudited Audited I Income from Operations Sales 49,744.73 41,750.91 44,962.85 91,495.64 90,063.12 1
Slide 29: CSR Established in 2010
Nectar Polytechnic for Women Malnutrition and Safe Drinking Water CSR Welfare of Animals Eradicating Hunger Promoting Healthcare and Preventive Healthcare Established in 2010 Mission: To elevate its status to a center of excellence in Women’s technical education by a conscious and consistent enhance
Slide 30: Awards and Accolades
AWARDS AND ACCOLADES Ranked 412 in Fortune India 500 Outstanding Export Performance award in Currently Ranked 419 Amongst Indian companies API by Pharmexcil Companies by Economic Times Year 2019 Year 2019 Year 2019 National Energy Conservation Award National Energy Conservation Award "Certificate of
Slide 31: Thank You
THANK YOU
Nectar Lifesciences — Q2 FY2025 Earnings Presentation on 6ix